Symbols / GUTS Stock $0.92 +12.75% Fractyl Health, Inc.

Healthcare • Biotechnology • United States • NGM
GUTS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Harith Rajagopalan M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 146.16M
Enterprise Value 143.81M
Income -108.00M
Sales —
FCF (ttm) -51.71M
Book/sh 0.14
Cash/sh 0.40
Employees 100
Insider 10d —
IPO Feb 02, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.69
PEG —
P/S —
P/B 6.63
P/C —
EV/EBITDA -1.57
EV/Sales —
Quick Ratio 4.10
Current Ratio 4.28
Debt/Eq 284.50
LT Debt/Eq —
EPS (ttm) -1.31
EPS next Y -0.54
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-11
Earnings (prior) 2026-03-24
ROA -63.64%
ROE -7.78%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 158.65M
Shs Float 136.13M
Insider Own 1.31%
Instit Own 52.47%
Short Float 2.03%
Short Ratio 1.81
Short Interest 3.01M
52W High 3.03
vs 52W High -69.59%
52W Low 0.38
vs 52W Low 144.38%
Beta —
Impl. Vol. —
Rel Volume 0.69
Avg Volume 2.32M
Volume 1.60M
Target (mean) $5.24
Tgt Median $6.20
Tgt Low $2.00
Tgt High $8.00
# Analysts 5
Recom Strong_buy
Prev Close $0.82
Price $0.92
Change 12.75%
About

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.24
Mean price target
2. Current target
$0.92
Latest analyst target
3. DCF / Fair value
$-5.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.92
Low
$2.00
High
$8.00
Mean
$5.24

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-24 reit HC Wainwright & Co. Buy → Buy $8
2026-03-26 main Canaccord Genuity Buy → Buy $8
2026-01-30 down Morgan Stanley Overweight → Equal-Weight $2
2025-12-02 reit HC Wainwright & Co. Buy → Buy $8
2025-11-21 main Canaccord Genuity Buy → Buy $8
2025-09-26 main HC Wainwright & Co. Buy → Buy $8
2025-09-15 init HC Wainwright & Co. — → Buy $9
2025-08-28 init Ladenburg Thalmann — → Buy $4
2025-08-14 main Canaccord Genuity Buy → Buy $6
2025-04-15 init Canaccord Genuity — → Buy $12
2025-02-03 main Morgan Stanley Overweight → Overweight $10
2024-02-28 init Evercore ISI Group — → Outperform —
2024-02-27 init Morgan Stanley — → Overweight $18
News
RSS: Latest GUTS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-04 RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer — 10,416 $1.92 $19,999
2025-03-14 ROYAN AJAY G. Director and Beneficial Owner of more than 10% of a Class of Security — 17,901 $1.28 $22,980
2025-03-14 BARNES KELLY ANN Director — 31,000 $1.30 $40,210
2025-03-13 BRADLEY WILLIAM C Director — 16,129 $1.26 $20,358
2025-03-13 SCHULMAN AMY W. Director — 8,550 $1.17 $9,964
2025-03-13 CONAWAY SAMUEL Director — 8,550 $1.17 $9,964
2025-01-31 CAPLAN JAY DAVID President — 43,818 $1.81 $82,266
2025-01-31 RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer — 111,920 $1.82 $206,003
2025-01-31 CAPLAN JAY DAVID President — 43,818 $1.70 $74,491
2025-01-31 RAJAGOPALAN HARITH M.D., PH.D. Chief Executive Officer — 111,920 $1.70 $190,264
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.09
-22.50%
0.12
0.00
Operating Revenue
0.00
-100.00%
0.09
-22.50%
0.12
0.00
Cost Of Revenue
0.00
-100.00%
0.05
-35.06%
0.08
0.00
Reconciled Cost Of Revenue
0.00
-100.00%
0.05
-35.06%
0.08
0.00
Gross Profit
0.00
-100.00%
0.04
+0.00%
0.04
0.00
Operating Expense
96.82
+3.46%
93.57
+83.91%
50.88
+3.03%
49.38
Research And Development
74.54
+5.77%
70.47
+85.26%
38.04
+10.72%
34.35
Selling General And Administration
22.28
-3.56%
23.10
+79.92%
12.84
-14.57%
15.03
General And Administrative Expense
—
—
—
15.03
Other Gand A
—
—
—
15.03
Total Expenses
96.82
+3.41%
93.62
+83.73%
50.96
+3.18%
49.38
Operating Income
-96.82
-3.51%
-93.53
-83.99%
-50.84
-2.94%
-49.38
Total Operating Income As Reported
-96.82
-3.51%
-93.53
-83.99%
-50.84
-2.94%
-49.38
EBITDA
-95.69
-3.05%
-92.85
-83.69%
-50.55
-3.30%
-48.93
Normalized EBITDA
-54.79
+50.54%
-110.76
-153.14%
-43.76
+10.26%
-48.76
Reconciled Depreciation
1.13
+66.77%
0.68
+136.71%
0.29
-36.73%
0.45
EBIT
-96.82
-3.51%
-93.53
-83.99%
-50.84
-2.94%
-49.38
Total Unusual Items
-40.90
-328.40%
17.91
+363.59%
-6.79
-3760.23%
-0.18
Total Unusual Items Excluding Goodwill
-40.90
-328.40%
17.91
+363.59%
-6.79
-3760.23%
-0.18
Special Income Charges
—
—
0.00
+100.00%
-0.31
Other Special Charges
—
—
—
0.31
Net Income
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Pretax Income
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Net Non Operating Interest Income Expense
1.54
-62.86%
4.15
+229.05%
1.26
+58.09%
0.80
Interest Expense Non Operating
—
—
—
—
Net Interest Income
1.54
-62.86%
4.15
+229.05%
1.26
+58.09%
0.80
Interest Expense
—
—
—
—
Interest Income Non Operating
1.54
-62.86%
4.15
+229.05%
1.26
+58.09%
0.80
Interest Income
1.54
-62.86%
4.15
+229.05%
1.26
+58.09%
0.80
Other Income Expense
-45.68
-320.76%
20.69
+175.20%
-27.52
-1388.76%
2.13
Other Non Operating Income Expenses
-4.78
-271.65%
2.78
+113.43%
-20.72
-996.62%
2.31
Gain On Sale Of Security
-40.90
-328.40%
17.91
+363.59%
-6.79
-5059.12%
0.14
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Net Income From Continuing Operation Net Minority Interest
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Net Income From Continuing And Discontinued Operation
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Net Income Continuous Operations
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Normalized Income
-100.05
-15.53%
-86.60
-23.19%
-70.30
-51.90%
-46.28
Net Income Common Stockholders
-140.95
-100.13%
-70.43
+25.29%
-94.27
-48.15%
-63.63
Diluted EPS
-0.92
+43.27%
-1.62
+18.28%
-1.98
-48.32%
-1.34
Basic EPS
-0.92
+43.27%
-1.62
+18.28%
-1.98
-48.32%
-1.34
Basic Average Shares
153.37
+252.24%
43.54
-8.54%
47.61
+0.00%
47.61
Diluted Average Shares
153.37
+252.24%
43.54
-8.54%
47.61
-42.24%
82.43
Diluted NI Availto Com Stockholders
-140.95
-100.13%
-70.43
+25.29%
-94.27
-48.15%
-63.63
Preferred Stock Dividends
—
1.74
-89.89%
17.18
+0.00%
17.18
Total Other Finance Cost
—
—
—
-0.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
121.40
+12.33%
108.08
+41.81%
76.21
+25.03%
60.96
Current Assets
87.58
+22.04%
71.76
+101.31%
35.65
-30.95%
51.63
Cash Cash Equivalents And Short Term Investments
81.54
+20.86%
67.46
+103.15%
33.21
-32.60%
49.27
Cash And Cash Equivalents
81.54
+20.86%
67.46
+103.15%
33.21
-32.60%
49.27
Receivables
—
0.00
-100.00%
0.02
0.00
Accounts Receivable
—
0.00
-100.00%
0.02
0.00
Inventory
0.00
-100.00%
0.07
+0.00%
0.07
0.00
Restricted Cash
—
0.00
-100.00%
0.32
0.00
Other Current Assets
6.04
+42.83%
4.23
+108.28%
2.03
-14.03%
2.36
Total Non Current Assets
33.83
-6.85%
36.31
-10.48%
40.56
+334.91%
9.33
Net PPE
29.23
-6.88%
31.39
+2.02%
30.77
+1768.37%
1.65
Gross PPE
31.96
-3.12%
32.99
-7.34%
35.60
+474.98%
6.19
Accumulated Depreciation
-2.72
-70.78%
-1.59
+66.98%
-4.83
-6.29%
-4.54
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.76
+0.00%
1.76
+105.86%
0.85
+1.07%
0.84
Construction In Progress
0.09
+0.00%
0.09
+22.08%
0.08
+92.50%
0.04
Other Properties
29.51
-3.37%
30.54
-1.19%
30.91
+1577.90%
1.84
Leases
0.60
+0.00%
0.60
-84.09%
3.77
+8.66%
3.47
Other Non Current Assets
4.59
-6.69%
4.92
-49.74%
9.79
+27.50%
7.68
Total Liabilities Net Minority Interest
111.94
+40.54%
79.65
-80.15%
401.27
+28.09%
313.27
Current Liabilities
18.33
-7.31%
19.77
+76.75%
11.19
+53.03%
7.31
Payables And Accrued Expenses
12.26
-12.32%
13.99
+77.47%
7.88
+30.82%
6.03
Payables
1.57
-51.42%
3.24
+485.90%
0.55
-43.57%
0.98
Accounts Payable
1.57
-51.42%
3.24
+485.90%
0.55
-43.57%
0.98
Current Accrued Expenses
10.69
-0.54%
10.75
+46.65%
7.33
+45.27%
5.04
Current Debt And Capital Lease Obligation
5.10
+2.99%
4.96
+81.47%
2.73
+118.48%
1.25
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
5.10
+2.99%
4.96
+81.47%
2.73
+118.48%
1.25
Current Deferred Liabilities
—
—
—
—
Other Current Liabilities
0.96
+15.64%
0.83
+44.52%
0.57
+1497.22%
0.04
Total Non Current Liabilities Net Minority Interest
93.61
+56.34%
59.88
-84.65%
390.09
+27.49%
305.96
Long Term Debt And Capital Lease Obligation
56.54
-1.74%
57.54
-31.22%
83.66
+359.04%
18.23
Long Term Debt
30.59
+1.41%
30.16
-45.31%
55.15
+210.54%
17.76
Long Term Capital Lease Obligation
25.96
-5.21%
27.38
-3.95%
28.51
+6030.75%
0.47
Non Current Deferred Liabilities
—
—
—
—
Other Non Current Liabilities
0.66
-33.57%
1.00
—
0.00
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
287.33
+0.00%
287.33
Stockholders Equity
9.46
-66.73%
28.42
+108.74%
-325.06
-28.83%
-252.32
Common Stock Equity
9.46
-66.73%
28.42
+108.74%
-325.06
-28.83%
-252.32
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
153.37
+214.57%
48.76
+1.79%
47.90
+0.72%
47.55
Ordinary Shares Number
153.37
+214.57%
48.76
+1.79%
47.90
+0.72%
47.55
Additional Paid In Capital
565.72
+27.49%
443.73
+1958.71%
21.55
+25.27%
17.21
Retained Earnings
-556.26
-33.94%
-415.31
-19.82%
-346.62
-28.60%
-269.52
Total Equity Gross Minority Interest
9.46
-66.73%
28.42
+108.74%
-325.06
-28.83%
-252.32
Total Capitalization
40.04
-31.65%
58.59
+121.71%
-269.91
-15.07%
-234.56
Working Capital
69.25
+33.20%
51.99
+112.54%
24.46
-44.81%
44.32
Invested Capital
40.04
-31.65%
58.59
+121.71%
-269.91
-15.07%
-234.56
Total Debt
61.65
-1.37%
62.50
-27.65%
86.39
+343.60%
19.48
Net Debt
—
—
21.94
—
Capital Lease Obligations
31.06
-3.95%
32.34
+3.52%
31.24
+1721.52%
1.72
Net Tangible Assets
9.46
-66.73%
28.42
+108.74%
-325.06
-28.83%
-252.32
Tangible Book Value
9.46
-66.73%
28.42
+108.74%
-325.06
-28.83%
-252.32
Derivative Product Liabilities
36.41
+2625.30%
1.34
-93.00%
19.10
+4591.89%
0.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-90.33
-37.86%
-65.52
-53.00%
-42.82
+7.40%
-46.24
Cash Flow From Continuing Operating Activities
-90.33
-37.86%
-65.52
-53.00%
-42.82
+7.40%
-46.24
Net Income From Continuing Operations
-140.95
-105.19%
-68.69
+10.89%
-77.09
-65.95%
-46.45
Depreciation Amortization Depletion
1.13
+66.77%
0.68
+136.71%
0.29
-36.73%
0.45
Depreciation
1.13
+66.77%
0.68
+136.71%
0.29
-36.73%
0.45
Depreciation And Amortization
1.13
+66.77%
0.68
+136.71%
0.29
-36.73%
0.45
Other Non Cash Items
2.31
+163.84%
-3.61
-116.50%
21.90
+1046.13%
-2.31
Stock Based Compensation
6.68
-53.67%
14.43
+235.80%
4.30
+36.90%
3.14
Operating Gains Losses
40.90
+328.40%
-17.91
-363.59%
6.79
+3738.42%
0.18
Gain Loss On Investment Securities
40.90
+328.40%
-17.91
-363.59%
6.79
+5059.12%
-0.14
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.00
Change In Working Capital
-0.40
-104.12%
9.59
+869.87%
0.99
+179.63%
-1.24
Change In Receivables
0.00
-100.00%
0.02
+200.00%
-0.02
0.00
Changes In Account Receivables
0.00
-100.00%
0.02
+200.00%
-0.02
0.00
Change In Inventory
0.07
0.00
+100.00%
-0.07
0.00
Change In Prepaid Assets
2.25
+202.32%
-2.20
-763.75%
0.33
+122.91%
-1.45
Change In Payables And Accrued Expense
-1.25
-115.01%
8.34
+7089.66%
0.12
+112.62%
-0.92
Change In Accrued Expense
0.41
-92.68%
5.65
+941.25%
0.54
+158.45%
-0.93
Change In Payable
-1.67
-162.03%
2.69
+729.04%
-0.43
-4370.00%
0.01
Change In Account Payable
-1.67
-162.03%
2.69
+729.04%
-0.43
-4370.00%
0.01
Change In Other Working Capital
-0.19
-107.99%
2.33
+3047.30%
0.07
-93.40%
1.12
Change In Other Current Liabilities
-1.28
-216.39%
1.10
+95.03%
0.56
—
Investing Cash Flow
-0.56
+68.44%
-1.76
-391.64%
-0.36
-541.07%
-0.06
Cash Flow From Continuing Investing Activities
-0.56
+68.44%
-1.76
-391.64%
-0.36
-541.07%
-0.06
Net PPE Purchase And Sale
-0.56
+68.44%
-1.76
-391.64%
-0.36
-541.07%
-0.06
Purchase Of PPE
-0.56
+68.44%
-1.76
-391.64%
-0.36
-541.07%
-0.06
Capital Expenditure
-0.56
+68.44%
-1.76
-391.64%
-0.36
-541.07%
-0.06
Financing Cash Flow
104.96
+3.69%
101.23
+268.94%
27.44
+530.74%
4.35
Cash Flow From Continuing Financing Activities
104.96
+3.69%
101.23
+268.94%
27.44
+530.74%
4.35
Net Issuance Payments Of Debt
-0.46
-144.39%
-0.19
-100.66%
28.35
+603.60%
4.03
Issuance Of Debt
—
0.00
-100.00%
28.43
+41.63%
20.07
Repayment Of Debt
-0.46
-144.39%
-0.19
-122.62%
-0.08
+99.48%
-16.05
Long Term Debt Issuance
—
0.00
-100.00%
28.43
+41.63%
20.07
Long Term Debt Payments
-0.46
-144.39%
-0.19
-122.62%
-0.08
+99.48%
-16.05
Net Long Term Debt Issuance
-0.46
-144.39%
-0.19
-100.66%
28.35
+603.60%
4.03
Short Term Debt Payments
—
—
—
-16.04
Net Short Term Debt Issuance
—
—
—
-16.04
Net Common Stock Issuance
85.40
-17.64%
103.69
0.00
—
Proceeds From Stock Option Exercised
20.02
+3399.48%
0.57
+1000.00%
0.05
-83.80%
0.32
Net Other Financing Charges
—
-2.85
-196.37%
-0.96
—
Changes In Cash
14.08
-58.53%
33.94
+315.56%
-15.74
+62.47%
-41.95
Beginning Cash Position
71.72
+89.84%
37.78
-29.42%
53.52
-43.94%
95.47
End Cash Position
85.80
+19.63%
71.72
+89.84%
37.78
-29.42%
53.52
Free Cash Flow
-90.89
-35.07%
-67.29
-55.82%
-43.18
+6.73%
-46.30
Interest Paid Supplemental Data
4.30
+37.51%
3.13
+310.37%
0.76
+10785.71%
0.01
Common Stock Issuance
85.40
-17.64%
103.69
0.00
—
Issuance Of Capital Stock
85.40
-17.64%
103.69
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category